International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

Allowing Compounding Pharmacies to Address Drug Shortages

Author(s): Broughel James

Issue: Mar/Apr 2022 - Volume 26, Number 2
View All Articles in Issue

Page(s): 100-109

Allowing Compounding Pharmacies to Address Drug Shortages Page 1

Allowing Compounding Pharmacies to Address Drug Shortages Page 2

Allowing Compounding Pharmacies to Address Drug Shortages Page 3

Allowing Compounding Pharmacies to Address Drug Shortages Page 4

Allowing Compounding Pharmacies to Address Drug Shortages Page 5

Allowing Compounding Pharmacies to Address Drug Shortages Page 6

Allowing Compounding Pharmacies to Address Drug Shortages Page 7

Allowing Compounding Pharmacies to Address Drug Shortages Page 8

Allowing Compounding Pharmacies to Address Drug Shortages Page 9

Allowing Compounding Pharmacies to Address Drug Shortages Page 10

Download in electronic PDF format for $75

Abstract: The U.S. has entered a new age of supply chain challenges, and while many of these challenges were unpredictable consequences of the COVID-19 pandemic, there are also some predictable shortages, including those that arise in the modern prescription drug market. In an effort to combat these foreseeable events, compounding pharmacies, or compounders, have the wherewithal to step in and address drug shortages when they occur. Whether they are able to assist, however, ultimately hinges not on their capabilities, but on whether they are allowed to assist under federal law.

Related Keywords: James Broughel, PhD, drug shortages, supply chain, Covid-19 pandemic, public policy, U.S. Food and Drug Administration, FDA Guidance for Industry, Federal Food, Drug, and Cosmetic Act section 503A, Federal Food, Drug, and Cosmetic Act section 503B, American Society of Health Systems Pharmacists, legislation

Related Categories: LEGAL, SUPPORT, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Allowing Compounding Pharmacies to Address Drug Shortages Broughel James	Mar/Apr 2022 Pg. 100-109
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic McElhiney Linda F	Jul/Aug 2020 Pg. 287-295
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Allen Loyd V Jr	Mar/Apr 2022 Pg. 92
The Role of Compounding Pharmacists During Drug Shortages Ofei Kelvin	Jul/Aug 2022 Pg. 298-301
Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Allen Loyd V Jr, Williams LaVonn A	Jul/Aug 2012 Pg. 294-298
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot Brunner Scott	Jul/Aug 2021 Pg. 296-297
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
PreScription: Shortages Continue--Compounding Pharmacies Fill the Gap…Again! Allen Loyd V Jr	May/Jun 2023 Pg. 180
PreScription: COVID-19 and Compounding Pharmacists Allen Loyd V Jr	Jul/Aug 2020 Pg. 268
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Lyon Joanna	Nov/Dec 2012 Pg. 456-460
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Return to Top